Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Nonmalignant Neoplasm: early-phase trial registry

2 of 4 indexed Nonmalignant Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Nonmalignant Neoplasm: 4 US clinical trials tracked, 2 recruiting.

Nonmalignant Neoplasm is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Roswell Park Cancer Institute, running 1 of these trials.

Enrollment posture brief

Registry condition nonmalignant-neoplasm

OPEN 2 | RECR 50% | LATE 0 | EARLY 2 | RANK #4115 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Nonmalignant Neoplasm (this)50%
Open-enrollment share among volume-matched conditions near Nonmalignant Neoplasm

Nonmalignant Neoplasm lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Nonmalignant Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Nonmalignant Neoplasm is recruiting above its size-band peers.

    2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Named interventions

Most-linked intervention names on Nonmalignant Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Immunoenzyme technique Other
1 trials
Laboratory biomarker analysis Other
1 trials
trivalent influenza vaccine Biological
1 trials
anti-thymocyte globulin Biological
1 trials
busulfan Drug
1 trials
etoposide Drug
1 trials
cyclophosphamide Drug
1 trials
carboplatin Drug
1 trials

US sites by state

Facility locations filed on Nonmalignant Neoplasm trials. A trial with sites in several states counts in each.

Washington 1 trials
New York 1 trials
North Carolina 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Nonmalignant Neoplasm page

4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Nonmalignant Neoplasm condition card totals 4 registered trials; most-linked intervention Immunoenzyme technique; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.